Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medicure Inc V.MPH

Alternate Symbol(s):  MCUJF

Medicure Inc. is a pharmaceutical company. It is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market. The focus of it is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company... see more

TSXV:MPH - Post Discussion

Medicure Inc > Message to Shareholders, November 2022
View:
Post by prophetoffactz on Nov 24, 2022 6:22pm

Message to Shareholders, November 2022

Message to Shareholders, November 2022

Medicure’s business growth now has four focuses:

AGGRASTAT® (tirofiban hydrochloride) injection continues to hold the majority of the patient market share in the US and contributed about $3 million to Medicure’s revenue for the quarter ended September 30th, 2022, a slight increase over the Q2 revenue. We continue to market the benefits of AGGRASTAT® and nurture brand loyalty.

ZYPITAMAG® (pitavastatin) sales continue to grow from Marley Drug and insured customers. The growth in sales is attributable to applying the learnings from the past couple of years, improved insurance coverage and with the addition of Marley Drug’s direct to consumer market for cash paying customers.

Marley Drug - Marley Drug fits well with our vision and provides excellent customer service, cost competitive medications, immediate direct to patient delivery, and is licensed in all 50 states, Washington D.C. and Puerto Rico. The E-commerce addition is still taking some time but we are exploring further partnerships to increase the customer base. The combined business will be well positioned to strengthen our existing national platforms, including accelerating the growth of ZYPITAMAG®, realizing on material synergies and generating substantial shareholder value.

MC-1 for PNPO – The Phase 3 Pivotal trial for treatment of Pyridoxal 5’-phosphate dependent epilepsy (PNPO deficiency) with the legacy product, MC-1 is now scheduled to begin in Q1 2023. For this indication, MC-1 has received Orphan Drug status and a Rare Pediatric Disease Designation from the FDA, providing significant value as we work diligently towards FDA approval.

Medicure remains focused on growing revenue and earnings with the existing business and further exploration of adding revenue generating products and businesses.

On behalf of the Board of Directors, I want to thank our shareholders, stakeholders and employees for their continued support while we manage our business. We remain committed to creating value for you, our valued shareholders.

Yours sincerely, Albert D. Friesen, Ph.D. Chairman and Chief Executive Officer
Comment by Winnipeg40 on Nov 25, 2022 8:44am
New entrant for Aggrastat allowed into the Market this month and completely off patent in Q1.   Zypitimag sales not growing all that fast to replace and Marley Drugs under MPH Management has had decreasing sales since being aquired.  Wait for possible devaluation at year end.   enjoy a quarter or two.....then Aggrastat sales will plummet...Note that all improvement is cost ...more  
Comment by prophetoffactz on Nov 25, 2022 12:36pm
"New entrant for Aggrastat allowed into the Market this month and completely off patent in Q1." MPH has no knowledge that it was launched this month according to the conference call. It was only for one format. When competing products went generic it also went a long way to genericizing AGGRASTAT as MPH had to compete on price. MPH only has about US$10 million in annual US AGGRASTAT ...more  
Comment by Winnipeg40 on Nov 28, 2022 12:32pm
Appears real investors agree,  leaving the MPH share price where it was prior to the announcement.    Comparing first 9 months of 2021 Vs 2022 not relevant.  Have to look at quarter to quarter growth...and that is not happening in any significant way.  MPH outsources its manufacturing, the generics will do it in house so can easily undercut...and at the end of the day ...more  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities